InvestorsHub Logo
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 5329

Tuesday, 05/02/2023 10:18:19 AM

Tuesday, May 02, 2023 10:18:19 AM

Post# of 6093
PFE reports 1Q23 results—reiterates 2023 guidance:

https://s28.q4cdn.com/781576035/files/doc_financials/2023/q1/Q1-2023-PFE-Earnings-Release.pdf

Reiterated 2023 guidance is: $3.25-3.45 of non-GAAP EPS; $67-71M of revenue including $21.5B for COVID products ($13.5B Comirnaty, $8B Paxlovid); and organic sales growth excluding COVID products of 7-9%.

1Q23 COVID sales were $7.1B ($2.9B Comirnaty, $4.1B Paxlovid).

CC slides:
https://s28.q4cdn.com/781576035/files/doc_financials/2023/q1/Q1-2023-Earnings-Charts-FINAL.pdf

Prepared CC remarks (synched with slides):
https://s28.q4cdn.com/781576035/files/doc_financials/2023/q1/Q1-2023-Earnings-Conference-Call-Prepared-Remarks-FINAL.pdf

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PFE News